Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Most plateaus can be addressed through protocol adjustments rather than increasing your dose or switching medications
Your practitioner will guide you on the best schedule based on your individual health
you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects
For longer use, periodic breaks and routine health check-ups are advisable
Promotes breakdown of liver fat (hepatic steatosis): GCGR activity boosts fatty acid oxidation in the liver, explaining marked reductions in hepatic fat seen in trials 1,2
US$ 23.93
US$ 24.86
US$ 22.92
